Galactosyltransferases in glycosaminoglycan synthesis pathway

Galactosyltransferases in the glycosaminoglycan (GAG) synthesis pathway, primarily Beta-1,4-galactosyltransferase 7 (B4GALT7) and Beta-1,3-galactosyltransferase 6 (B3GALT6), are essential enzymes that catalyze the formation of the tetrasaccharide linkage region (GlcUA-Gal-Gal-Xyl) on proteoglycans (UniProt Q9UBF8, Q96L58). These enzymes are responsible for the sequential addition of two galactose residues to a xylose-serine primer, a critical step for the subsequent polymerization of GAG chains like heparan sulfate and chondroitin sulfate (NCBI Bookshelf, NBK1900). Located in the Golgi apparatus, they play a fundamental role in maintaining the structural integrity and signaling capacity of the extracellular matrix. Genetic mutations in the genes encoding these enzymes lead to a group of rare connective tissue disorders known as linkeropathies, most notably the spondylodysplastic form of Ehlers-Danlos syndrome (PMID: 23824088). Patients with these conditions often exhibit skeletal dysplasia, joint hypermobility, and skin fragility due to impaired GAG synthesis (PMID: 28306229). While no FDA-approved drugs currently target these enzymes directly, they are significant targets in glycobiology research for understanding cell-matrix interactions. Small molecule xylosides, such as 4-methylumbelliferyl-beta-D-xyloside, are frequently used in experimental settings as decoy substrates to compete with the natural protein-bound xylose, thereby modulating GAG production (PMID: 11278875). Targeting these enzymes is also being explored in cancer research, as GAGs are known to influence tumor growth, angiogenesis, and metastasis (PMID: 24038661).

Other names

Beta-1,4-galactosyltransferase 7Beta-1,3-galactosyltransferase 6GalT-IGalT-IIXylosylprotein 4-beta-galactosyltransferaseGalactosyltransferase IGalactosyltransferase IIB4GALT7B3GALT6

Substrate decoys or competitive inhibition of the linkage region formation